Endocrine Abstracts

Background: Hypoparathyroidism, a rare endocrine disorder characterised by low serum calcium due to low or insufficient parathyroid hormone levels, most commonly occurs post-surgery although can also occur due to predisposing genetic conditions or idiopathically. Hypoparathyroidism requires long-term medical management to minimise complications and detrimental impacts on health-related quality of life. Few real-world studies, particularly in the UK, have quantified healthcare ...

Background: Individuals with hypoparathyroidism often experience a range of symptoms associated with reduced health-related quality of life (HRQoL) and work productivity. Conventional therapy aims to alleviate hypocalcemia and acute symptoms but fails to restore normal parathyroid hormone (PTH) physiology or improve HRQoL. In the PaTHway trial, 79% of participants treated with TransCon PTH vs. 5% placebo (P<0.0001) met the primary efficacy endpoint (normal serum c...

Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH). Individuals with chronic hypoparathyroidism managed with conventional therapy (active vitamin D and calcium) are at increased risk for renal complications and declines in renal function. In clinical trials, palopegteriparatide treatment enabled independence from conventional therapy (no active vitamin D and ≤600 mg/day elemental calcium) and maintained serum biochemistr...